Retrospective analysis of acute exacerbation of interstitial lung diseases with nanoparticle albumin-bound paclitaxel in patients with advanced lung cancer with preexisting interstitial lung disease

  • Authors:
    • Yuto Yasuda
    • Takashi Nomizo
    • Hiroaki Ozasa
    • Tomoko Funazo
    • Takahiro Tsuji
    • Hironori Yoshida
    • Yuichi Sakamori
    • Hiroki Nagai
    • Tomohiro Handa
    • Takeshi Kubo
    • Young Hak Kim
  • View Affiliations

  • Published online on: August 11, 2017     https://doi.org/10.3892/mco.2017.1373
  • Pages:677-680
0

Abstract

Lung cancer with preexisting interstitial lung disease (ILD) is difficult to treat due to the risk of acute exacerbation of ILD. Nanoparticle albumin-bound (nab‑) paclitaxel improves the overall response rate and reduces neuropathy more efficiently compared with conventional solvent‑based (sb‑) paclitaxel in patients with advanced non‑small‑cell lung cancer. However, it is not known whether the risk of acute exacerbation of ILD with nab‑paclitaxel is higher compared with that with sb-paclitaxel. Advanced lung cancer patients with ILD treated with nab‑paclitaxel (n=14) or sb‑paclitaxel (n=14) were retrospectively reviewed. Acute exacerbation of ILD developed in 1/14 patients (7.7%) receiving nab‑paclitaxel and 3/14 patients (21.4%) receiving sb‑paclitaxel; the difference was not statistically significant. To the best of our knowledge, this is the first study to compare the incidence of acute exacerbation of ILD with nab‑paclitaxel with that of sb‑paclitaxel in patients with advanced lung cancer with preexisting ILD. The results of the present study support conducting a prospective clinical trial to confirm the clinical benefit of this agent.

Related Articles

Journal Cover

October 2017
Volume 7 Issue 4

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Yasuda, Y., Nomizo, T., Ozasa, H., Funazo, T., Tsuji, T., Yoshida, H. ... Kim, Y.H. (2017). Retrospective analysis of acute exacerbation of interstitial lung diseases with nanoparticle albumin-bound paclitaxel in patients with advanced lung cancer with preexisting interstitial lung disease. Molecular and Clinical Oncology, 7, 677-680. https://doi.org/10.3892/mco.2017.1373
MLA
Yasuda, Y., Nomizo, T., Ozasa, H., Funazo, T., Tsuji, T., Yoshida, H., Sakamori, Y., Nagai, H., Handa, T., Kubo, T., Kim, Y. H."Retrospective analysis of acute exacerbation of interstitial lung diseases with nanoparticle albumin-bound paclitaxel in patients with advanced lung cancer with preexisting interstitial lung disease". Molecular and Clinical Oncology 7.4 (2017): 677-680.
Chicago
Yasuda, Y., Nomizo, T., Ozasa, H., Funazo, T., Tsuji, T., Yoshida, H., Sakamori, Y., Nagai, H., Handa, T., Kubo, T., Kim, Y. H."Retrospective analysis of acute exacerbation of interstitial lung diseases with nanoparticle albumin-bound paclitaxel in patients with advanced lung cancer with preexisting interstitial lung disease". Molecular and Clinical Oncology 7, no. 4 (2017): 677-680. https://doi.org/10.3892/mco.2017.1373